SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
November 9, 2011
Date of Report (Date of earliest event reported)
JAZZ PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
(State or Other Jurisdiction
3180 Porter Drive, Palo Alto, California 94304
(Address of principal executive offices, including zip code)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|x||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|x||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 8.01. Other Events.
Jazz Pharmaceuticals, Inc. (the Company) previously announced a proposed business combination (the Merger) with Azur Pharma Public Limited Company (formerly Azur Pharma Limited), a public limited company formed under the laws of Ireland (Azur Pharma). In connection with the Merger, on October 26, 2011, Azur Pharma filed with the Securities and Exchange Commission (the SEC) a registration statement on Form S-4 (File No. 333-177528), as amended on November 9, 2011, that included the Companys preliminary proxy statement that was filed separately on the same day and that also constituted a preliminary prospectus of Azur Pharma regarding the Merger. On November 10, 2011, the registration statement was declared effective by the SEC.
The Company has set the date for the special meeting of the stockholders of the Company at which the Companys stockholders will consider approval of the Merger and the related matters for Monday, December 12, 2011, at 10:00 a.m. local time at the Companys principal executive offices located at 3180 Porter Drive, Palo Alto, California 94304. Assuming approval by the Companys stockholders of the proposed Merger and satisfaction or waiver of all closing conditions, the Company currently anticipates the closing of the Merger will take place in January 2012.
Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements about the anticipated consummation of the Merger and other statements that are not historical facts. These forward-looking statements are based on the Companys current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the Companys ability to complete the transaction on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the closing conditions related to the Merger. There can be no assurance that the Company will be able to complete the Merger on the anticipated terms, or at all. Additional risks and uncertainties relating to the Company and its business can be found under the caption Risk Factors and elsewhere in the Companys SEC filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, which are available at the SECs web site http://www.sec.gov. The Company undertakes no duty or obligation to update any forward-looking statements contained in this Current Report on Form 8-K as a result of new information, future events or changes in its expectations.
Additional Information and Where to Find It
In connection with the proposed Merger, the Company and Azur Pharma have filed documents with the SEC, including the filing by the Company of a definitive proxy statement/prospectus relating to the proposed Merger and the matters described above, and the filing by Azur Pharma of a registration statement on Form S-4 that includes the proxy statement/prospectus relating to the proposed Merger and the matters described above. The registration statement has been declared effective by the SEC and a definitive proxy statement/prospectus has been be filed with the SEC by the Company and is being mailed to the Companys stockholders in connection with the proposed Merger. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED DEFINITIVE PROXY STATEMENT/PROSPECTUS BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, AZUR PHARMA, THE PROPOSED MERGER AND THE MATTERS DESCRIBED ABOVE. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SECs web site at www.sec.gov, by directing a request to the Companys Investor Relations department at Jazz Pharmaceuticals, Inc., Attention: Investor Relations, 3180 Porter Drive, Palo Alto, California 94304, or to the Companys Investor Relations department at 650-496-2800 or by email to firstname.lastname@example.org. Investors and security holders may obtain free copies of the documents filed with the SEC on the Companys website at www.jazzpharmaceuticals.com under the heading Investors and then under the heading SEC Filings.
The Company and its directors and executive officers and Azur Pharma and its directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of the Company in connection with the proposed Merger. Information regarding these directors and executive officers and their special interests in the proposed Merger is included in the definitive proxy statement/prospectus described above. Additional information regarding the directors and executive officers of the Company is also included in the Companys proxy statement for its 2011 Annual Meeting of Stockholders, which was filed with the SEC on April 12, 2011. These documents are available free of charge at the SECs web site at www.sec.gov and from Investor Relations at the Company as described above.
This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|JAZZ PHARMACEUTICALS, INC.|
/s/ Bruce C. Cozadd
|Bruce C. Cozadd|
|Chairman and Chief Executive Officer|
Date: November 10, 2011